Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?

Int J Environ Res Public Health. 2021 Jul 18;18(14):7629. doi: 10.3390/ijerph18147629.

Abstract

The heterogeneous group of myelodysplastic syndromes (MDS) needs an individualized and patient-tailored therapeutic approach. Consensus-based guidelines for diagnosis and treatment provide a basis for clinical decision making. MDS guidelines are issued by expert panels. Our main objective was to examine how guidelines influence patients' adherence to expert recommendations and how they ensure healthcare quality. To approach this question, we reviewed the most common guidelines for diagnosing and treating MDS in adult patients. Furthermore, we critically looked at quality indicators for everyday practice and studied adherence in an everyday outpatient setting. Finally, we also paid close attention to patient-reported outcome measures and studied how they are used as endpoints in clinical trials. We can conclude that the combination of evidence-based diagnostic tools, standardized treatment recommendations, and patient-centered shared decision making will eventually lead to a healthcare standard that will significantly improve outcomes in adult patients with MDS.

Keywords: guidelines; myelodysplastic syndromes; patient reported outcome; prognosis.

Publication types

  • Review

MeSH terms

  • Adult
  • Consensus
  • Humans
  • Myelodysplastic Syndromes* / diagnosis
  • Myelodysplastic Syndromes* / therapy